Cadre Hldgs (NYSE:CDRE) 주식

Cadre Hldgs

Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.

Cadre Holdings Inc

Kronos Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRO#NYSE">KRO</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.14 by 14.29 percent. This is a 128.57 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $489.80 million which missed the analyst consensus estimate of $501.38 million by 2.31 percent. This is a 2.30 percent increase over sales of $478.80 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Kronos Worldwide Q1 EPS $0.16 Beats $0.14 Estimate, Sales $489.80M Miss $501.38M Estimate

WIIM

LegalZoom.com shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance with its midpoint above estimates. Also, the company issued FY25 sales guidance above estimates.

SCNI

Scinai Immunotherapeutics 2024 Revenue $658K

QTWO

Q2 Holdings shares are trading higher after the company raised its FY25 sales guidance above the estimate.

STAA

STAAR Surgical shares are trading lower after the company reported mixed Q1 financial results.

DLH Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLHC#NASDAQ">DLHC</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.07 by 14.29 percent. This is a 50 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $89.21 million which missed the analyst consensus estimate of $90.00 million by 0.88 percent. This is a 11.68 percent decrease over sales of $101.01 million the same period last year.

DLHC

DLH Hldgs Q2 EPS $0.06 Misses $0.07 Estimate, Sales $89.21M Miss $90.00M Estimate

F&amp;G Annuities &amp; Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FG#NYSE">FG</a>) reported quarterly earnings of $0.72 per share which missed the analyst consensus estimate of $0.96 by 25 percent. This is a 16.28 percent decrease over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $908.00 million which missed the analyst consensus estimate of $1.47 billion by 38.36 percent. This is a 42.13 percent decrease over sales of $1.57 billion the same period last year.

F&G Annuities & Life Q1 Adj. EPS $0.72 Misses $0.96 Estimate, Sales $908.00M Miss $1.47B Estimate

Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) reported quarterly earnings of $3.03 per share which beat the analyst consensus estimate of $2.93 by 3.41 percent. This is a 6.32 percent increase over earnings of $2.85 per share from the same period last year. The company reported quarterly sales of $1.95 billion which beat the analyst consensus estimate of $1.82 billion by 7.22 percent. This is a 18.44 percent increase over sales of $1.65 billion the same period last year.

Atmos Energy Q2 GAAP EPS $3.03 Beats $2.93 Estimate, Sales $1.95B Beat $1.82B Estimate

Innoviva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVA#NASDAQ">INVA</a>) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $0.38 by 294.74 percent. This is a 260.87 percent decrease over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $88.63 million which beat the analyst consensus estimate of $82.67 million by 7.21 percent. This is a 14.37 percent increase over sales of $77.50 million the same period last year.

INVA

Innoviva Q1 EPS $(0.74) Misses $0.38 Estimate, Sales $88.63M Beat $82.67M Estimate

Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.57 by 3.18 percent. This is a 0.62 percent increase over earnings of $1.61 per share from the same period last year. The company reported quarterly sales of $102.00 million which missed the analyst consensus estimate of $102.21 million by 0.20 percent. This is a 2.26 percent increase over sales of $99.74 million the same period last year.

REPX

Riley Exploration Permian Q1 Adj. EPS $1.62 Beats $1.57 Estimate, Sales $102.00M Miss $102.21M Estimate

IonQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) reported financial results for the first quarter Wednesday after the market close. Here&#8217;s an overview of the <a href="https://www.benzinga.com/pressreleases/25/05/b45266510/ionq-announces-first-quarter-financial-results">quantum computing company&#8217;s report</a>.
<ul>
<li>Q1 Revenue: $7.57 million, versus <a href="http://benzinga.com/quote/IONQ/earnings">estimates</a> of $7.51 million</li>
</ul>
<ul>
<li>Q1 Loss: 14 cents, versus estimates of 23 cents</li>
</ul>
IonQ ended the quarter with $697.1 million in cash, cash equivalents and investments.
&#8220;We delivered important commercialization and expansion milestones for both our quantum computing and quantum networking businesses,&#8221; said Niccolo de Masi, CEO of IonQ. 
&#8220;We&#8217;re delivering real-world value for our customers today, including a recent demonstration of a 12% speed improvement over classical computing in a simulation of a heart pump using quantum processed data and a production product by our partner Ansys.&#8221;
IonQ announced plans to acquire <a href="https://www.benzinga.com/pressreleases/25/05/b45265789/ionq-announces-intention-to-acquire-lightsynq-expediting-quantum-computing-quantum-internet-and-of">Lightsynq Technologies</a>, as well as plans to launch a global space-to-space and space-to-ground <a href="https://www.benzinga.com/pressreleases/25/05/b45266189/ionq-announces-plans-for-first-space-based-quantum-key-distribution-network">satellite quantum key distribution network</a> in connection with the earnings release.
Guidance: IonQ expects second-quarter organic and inorganic revenue of $16 million to $18 million versus estimates of $16.93 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company expects full-year 2025 organic and inorganic revenue to be in the range of $75 million to $95 million versus estimates of $85.42 million.
IONQ Price Action: <a href="https://www.benzinga.com/quote/IONQ" target="_blank" rel="noreferrer noopener">IonQ shares</a> were up 2.13% after hours, trading at $29.74 at the time of publication Wednesday, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/05/45261116/cisco-unveils-quantum-chip-and-lab-to-push-next-gen-networking">Cisco Unveils Quantum Chip And Lab To Push Next-Gen Networking</a></li>
</ul>
Photo: courtesy of IonQ.

Guidance

Movers

IONQ

IonQ Q1 Earnings: Revenue Beat, Smaller-Than-Expected Loss, Forward Guidance And More

Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/05/g45265863/fortinet-reports-first-quarter-2025-financial-results">from the report. </a>
The Details: Fortinet reported quarterly adjusted earnings of 58 cents per share, which beat the Street estimate of 53 cents. Quarterly revenue came in at $1.54 billion, in line with analysts&#8217; estimates.
Read Next: <a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says&nbsp;</a>
For the first quarter, Fortinet reported: 
<ul>
<li>Product Revenue:&nbsp;Product revenue was $459.1 million, an increase of 12.3% compared to $408.9 million for the same quarter of 2024.</li>
<li>Service Revenue:&nbsp;Service revenue was $1.08 billion, an increase of 14.4% compared to $944.4 million for the same quarter of 2024.</li>
<li>Billings:&nbsp;Total billings were $1.6 billion for the first quarter of 2025, an increase of 13.5% compared to $1.41 billion for the same quarter of 2024.</li>
<li>Remaining performance obligations:&nbsp;Remaining performance obligations were $6.49 billion as of March&nbsp;31, 2025, an increase of 11.7% compared to $5.81&nbsp;billion in the prior year&#8217;s quarter. </li>
</ul>
&#8220;We continue to accelerate our growth strategy by investing in the rapidly expanding Unified SASE and Security Operations markets, while strengthening our leadership in Secure Networking. Leveraging our deep expertise in networking and security convergence, a strong track record of AI-driven innovation, and seamless product development and integration through our FortiOS operating system, we have established ourselves as the leader in organic innovation and will continue setting the industry standard in cybersecurity,&#8221; said Ken Xie, CEO of Fortinet. 
Outlook:&nbsp;Fortinet raised its fiscal 2025 adjusted EPS guidance to a range of $2.43 to $2.49, versus the $2.47&nbsp;estimate and affirmed its revenue guidance of between $6.65 billion and $6.85 billion, versus the $6.76 billion estimate. 
FTNT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Fortinet stock was down 7.37% at $98.86 after-hours Wednesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45239803/sarepta-therapeutics-stock-plummets-after-q1-results-heres-why?utm_source=articleShare">Sarepta Therapeutics Stock Plummets After Q1 Results: Here&#8217;s Why&nbsp;</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Tech

FTNT

Fortinet Stock Sinks After Q1 Results: Earnings Beat, Revenues In-Line

Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) is looking for Q4 Adj EPS of $0.81-$1.01 vs $0.91 analyst estimate. sees sales of $1.425 billion-$1.575 billion vs $1.47 billion analyst estimate.

COHR

Coherent Sees Q4 Adj EPS $0.81-$1.01 vs $0.91 Est; Sees Sales $1.425B-$1.575B vs $1.47B Est

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) affirms FY2025 sales outlook from $545.00 million-$565.00 million to $545.00 million-$565.00 million vs $557.24 million estimate.

CPRX

Catalyst Pharmaceuticals Affirms FY2025 Sales Guidance of $545.00M-$565.00M vs $557.24M Est

Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.07 by 42.86 percent. This is a 42.86 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $48.26 million which beat the analyst consensus estimate of $43.83 million by 10.10 percent. This is a 21.07 percent increase over sales of $39.86 million the same period last year.

Envela Q1 EPS $0.10 Beats $0.07 Estimate, Sales $48.26M Beat $43.83M Estimate

Second Quarter 2025 Guidance
<ul>
<li>Revenue of $925 million, plus or minus $40 million</li>
<li>Gross margin of 46.5%, plus or minus 1.0%</li>
<li>GAAP operating expenses of $316 million, plus or minus $5 million and Non-GAAP operating expenses of $252 million, plus or minus $5 million</li>
<li>GAAP net income of $55 million, plus or minus $21 million and Non-GAAP net earnings of $106 million, plus or minus $19 million</li>
<li>GAAP net income per diluted share of $0.81, plus or minus $0.32 and Non-GAAP net earnings per diluted share of $1.56, plus or minus $0.28</li>
<li>Adjusted EBITDA of $216 million, plus or minus $23 million</li>
</ul>

MKSI

MKS Instruments Sees Q2 GAAP EPS $0.49-$1.13 vs $1.12 Est

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.53 by 28.3 percent. This is a 78.95 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $141.42 million which beat the analyst consensus estimate of $130.86 million by 8.07 percent. This is a 43.56 percent increase over sales of $98.51 million the same period last year.

Catalyst Pharmaceuticals Q1 Adj. EPS $0.68 Beats $0.53 Estimate, Sales $141.42M Beat $130.86M Estimate

Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.60) by 10 percent. This is a 40.54 percent increase over losses of $(1.11) per share from the same period last year. The company reported quarterly sales of $32.73 million which beat the analyst consensus estimate of $22.41 million by 46.03 percent. This is a 155.62 percent increase over sales of $12.80 million the same period last year.

XNCR

Xencor Q1 EPS $(0.66) Misses $(0.60) Estimate, Sales $32.73M Beat $22.41M Estimate

Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/05/g45265483/sunrun-reports-first-quarter-2025-financial-results"> from the report. </a>
The Details: Sunrun reported quarterly earnings of 20 cents per share, which beat the analyst consensus estimate of losses of 25 cents. Quarterly revenue came in at $504.27 million, which beat the consensus estimate of $484.06 million, and represented a 10% increase over revenue of $458.19 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says&nbsp;</a>
For the first quarter, Sunrun reported: 
<ul>
<li>Aggregate Subscriber Value of $1.2 billion, 23% growth year-over-year. </li>
<li>Contracted Net Value Creation of $164 million, 104% growth year-over-year. </li>
<li>Cash Generation of $56 million, the fourth consecutive quarter of positive cash generation. </li>
</ul>
&#8220;The first quarter was another strong quarter for Sunrun as we exceeded our volume and Cash Generation targets by significant margins in what is seasonally the slowest quarter of the year,&#8221;  said Mary Powell, Sunrun&#8217;s CEO. &#8220;We are focused on delivering the best product for customers, underwriting volumes with strong unit margins, optimizing our routes to market, and driving cost discipline, including leveraging AI for innovation, creating significant operating efficiencies and quality enhancement. This has allowed us to gain market share in recent periods and produce strong operating and financial results.&#8221;
RUN Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Sunrun stock was up 8.25% at $8.00 after hours Wednesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45239803/sarepta-therapeutics-stock-plummets-after-q1-results-heres-why?utm_source=articleShare">Sarepta Therapeutics Stock Plummets After Q1 Results: Here&#8217;s Why&nbsp;</a></li>
</ul>
Photo: Shutterstock

Sunrun Stock Rallies After Strong Q1 Report: Details

Tutor Perini shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 EPS guidance with its midpoint above estimates.

Press Releases

Cadre Holdings Announces Expansion to Credit Facilities

Cadre Holdings Appoints Gianmaria Delzanno to its Board of Directors

Cadre Holdings to Acquire Multiple Leading Nuclear Brands

Cadre Holdings Increases Dividend

Cadre Holdings to Announce Fourth Quarter and Full Year 2024 Earnings and 2025 Financial Guidance on March 11, 2025

Cadre Holdings Reports Fourth Quarter and Full Year 2024 Financial Results

Cadre Holdings Completes Acquisition of Carr's Engineering Division

Cadre Holdings Declares Quarterly Dividend of $0.095 Per Share

Cadre Holdings Announces First Quarter 2025 Earnings and Conference Call Information

Cadre Holdings Reports First Quarter 2025 Financial Results

CDRE

Archer Aviation Inc. Class A Common Stock

Archer Aviation

AerSale

Astronics

AeroVironment

Byrna Technologies

Ducommun

EHang Holdings

Eve Holding

Vertical Aerospace

Hexcel

Innovative Solutions and Support, Inc. - Common Stock

Innovative Solns

Karman Holdings

Kratos Defense & Security Solutions, Inc. - Common Stock

Kratos Defense & Security

Intuitive Machines, Inc. - Class A Common Stock

Intuitive Machines

Moog Inc. Class A Common Stock

Mercury Sys

National Presto Industries, Inc. Common Stock

National Presto Indus

Park Aerospace

Redwire

Satellogic

Virgin Galactic Holdings, Inc. Common Stock

Virgin Galactic Hldgs

Spirit Aerosystems Holdings, Inc. Common Stock

Spirit AeroSystems Hldgs

Triumph Group

Roth MKM

Stifel

B. Riley Securities

Stephens & Co.

B of A Securities

Cadre Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance above estimates.

Comments

Cadre Hldgs

뉴스

파트너 / 기고자

벤징가 글로벌